Mashup Score:1
HCPLive®Greater Hydroxyurea Doses, Adherence Linked to Improved Pediatric Sickle Cell Anemia Outcomes - 1 month
Mashup Score:1
Twitter Feed:
Mashup Score:1
HCPLive®Exercise Testing is Viable for Stable Sickle Cell Patients - 1 month
Mashup Score:1
A new study evaluates the prognostic potential of exercise testing for patients with sickle cell...
-
While exercise testing is often used as a prognostic marker in cardiovascular disease, the evidence surrounding exercise in patients with SCD is lacking. #SickleCell #SCD #RareDisease https://t.co/mHsP1gIWbK - view on twitter
Mashup Score:1
HCPLive®Non-Opioid Painkiller ACP-044 Fails to Meet Endpoint in Phase 2 Acute Pain Trial - 1 month
Mashup Score:1
Acadia Pharmaceuticals evaluated the effects of its novel redox modulator drug on pain intensity levels of patients undergoing a...
-
ACP-044 is also being examined for its role in treating pain associated with osteoarthritis of the knee in a phase 2 trial that's expected to conclude in the first half of 2023. #nonopioid #Rheum #Pain https://t.co/t5fMvZtFmI - view on twitter
Investigators address the need for understanding surrounding the relationship between poor bone health and patients who are hemophilia carriers and those with von Willebrand...
-
Investigators call for more research on poor bone health in patients with hemophilia, von Willebrand disease, and those who are hemophilia carriers. #HemophiliaDay #BleedingDisorder #Rheum https://t.co/MWI62N7TVY - view on twitter
Guidelines lack clear recommendations for osteoporosis management and fall prevention, which may be due to a lack of evidence in the...
-
A review of current #hemophilia guidelines found all contained inadequate recommendations for osteoporosis management and fall prevention in patients with hemophilia. https://t.co/zGAZk3hksj - view on twitter
More coverage:
#hemophilia
A systematic literature review highlighted key risk factors that could constitute a risk assessment model for hemophilia bleeding—a currently lacking guidance for...
-
A bleeding risk assessment model for #hemophilia is presently lacking. But investigators from @McMasterU uncovered factors that would likely influence such clinical guidance: https://t.co/wduFYOixdg - view on twitter
More coverage:
#hemophilia
Voxelotor is the first and only FDA-approved medication for children with sickle cell...
-
Voxelotor targets sickle hemoglobin polymerization. Read more about the HOPE-KIDS 1 trial just published in Pediatrics Blood & Cancer. #SCD #Oxbryta https://t.co/xPZJR1fQ83 - view on twitter
This episode features a conversation with Dr. Amelle Shillington and Jacob and Ashley Wiley after Shillington diagnosed the extremely rare genetic disease that’s afflicted...
-
This month, we focus on a disease with 70 documented cases worldwide and welcomed 3 guests to discuss the diagnosis of TANGO2 in 15-month old Aislynn Wiley. Listen to her story through her parents & Dr. Amelle Shillington @CincyChildrens @TANGO2Research https://t.co/t29B0qYP6p https://t.co/t29B0qYP6p - view on twitter
A study highlights methods to define hydroxyurea exposure as means of understanding hematologic benefit derived from the first-line drug for...
How can we begin to optimize hydroxyurea use among children with #SickleCell #anemia? Start off by better defining what "exposure" to the drug looks like: https://t.co/4lBlkSyCri - view on twitter